Predicting mortality and detecting severe disease
First Claim
Patent Images
1. A method of evaluating the efficacy of a treatment of Chronic Obstructive Pulmonary Disorder (COPD), pulmonary embolism, emphysema, lymphoma, or pericarditis in a subject having COPD, pulmonary embolism, emphysema, lymphoma, or pericarditis, the method comprising:
- selecting a subject having COPD, pulmonary embolism, emphysema, lymphoma, or pericarditis;
determining a level of soluble ST2 in a biological sample from the selected subject having COPD, pulmonary embolism, emphysema, lymphoma, or pericarditis at a first time point, wherein determining a level of soluble ST2 comprises contacting the biological sample with an antibody that specifically binds to soluble ST2;
identifying a subject that has an elevated level of soluble ST2 at the first time point compared to a reference level of soluble ST2;
administering a treatment to the identified subject;
determining a level of soluble ST2 in a biological sample from the identified subject at second time point following the administration of the treatment;
comparing the level of soluble ST2 in the biological sample at the second time point to the level of soluble ST2 in the biological sample at the first time point; and
identifying the administered treatment as being effective when there is a decrease in the level of soluble ST2 at the second time point compared to the level of soluble ST2 at the first time point.
1 Assignment
0 Petitions
Accused Products
Abstract
Measurement of circulating ST2 and/or IL-33 concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, and the detection of severe disease.
79 Citations
18 Claims
-
1. A method of evaluating the efficacy of a treatment of Chronic Obstructive Pulmonary Disorder (COPD), pulmonary embolism, emphysema, lymphoma, or pericarditis in a subject having COPD, pulmonary embolism, emphysema, lymphoma, or pericarditis, the method comprising:
-
selecting a subject having COPD, pulmonary embolism, emphysema, lymphoma, or pericarditis; determining a level of soluble ST2 in a biological sample from the selected subject having COPD, pulmonary embolism, emphysema, lymphoma, or pericarditis at a first time point, wherein determining a level of soluble ST2 comprises contacting the biological sample with an antibody that specifically binds to soluble ST2; identifying a subject that has an elevated level of soluble ST2 at the first time point compared to a reference level of soluble ST2; administering a treatment to the identified subject; determining a level of soluble ST2 in a biological sample from the identified subject at second time point following the administration of the treatment; comparing the level of soluble ST2 in the biological sample at the second time point to the level of soluble ST2 in the biological sample at the first time point; and identifying the administered treatment as being effective when there is a decrease in the level of soluble ST2 at the second time point compared to the level of soluble ST2 at the first time point. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)
-
Specification